Controlled release technologies have long been utilized as a method to enhance drug delivery and to maximize drug efficiency. API physicochemical and biopharmaceutic properties play a role in determining if the molecule is suitable for controlled release dosage forms. In this webinar, experts will share how dissolution tools and PBPK modeling can help evaluate whether a molecule is suitable for controlled release applications and predict the effects of release rate on in vitro performance. In addition, the experts will cover all aspects of oral controlled release technologies and discuss current strategies to select the optimal technology to meet the intended release profile.
- Overview of oral controlled release systems based on release mechanism and the latest insights into the development of in vivo predictive dissolution tools to establish in vitro–in vivo correlation (IVIVC)
- Development of the Gastrointestinal Simulator (GIS) to study drug release profiles of dosage forms and its extrapolation to non-disintegrating controlled release systems
- Key PK parameters needed for PBPK modelling of controlled release dosage forms and how to apply PBPK modelling to predict in vitro release profile needs
- Review of the selection criteria for controlled-release oral solid dosage forms and understanding of how a single-unit versus multiparticulate modified release systems modulate the release profile of the API